Nai-Kong Cheung MD PhD
Enid A. Haupt Chair in Pediatric Oncology, Member and Attending, Memorial Sloan Kettering Cancer Center, New York, NY
1275 York AvenueNew York, NY 10065
Overview of Dr. Cheung
Dr. Nai-Kong Cheung is a Pediatric Hematology & Oncology specialist based in New York, NY, holding the Enid A. Haupt Endowed Chair in Pediatric Oncology at Memorial Sloan Kettering Cancer Center. He completed his medical education at Harvard Medical School and Stanford University, where he also completed a residency and fellowship. Dr. Cheung's expertise lies in immunotherapy, neuroblastoma, and clinical research, among other areas. His research work has been published in prominent journals such as the Journal of Clinical Oncology, JAMA Oncology, JAMA, J. of Hematology & Oncology, Nature Genetics and Nature Communications. He has been involved in clinical trials focusing on neuroblastoma and other cancers. Dr. Cheung has received accolades such as America's Top Doctors and America's Top Doctors for Cancer from Castle Connolly, and Lifetime Achievement Award from the Advances in Neuroblastoma Research Association (ANRA).
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Pediatric Hematology/Oncology, 1980 - 1982- Stanford Health Care-Sponsored Stanford UniversityResidency, Pediatrics, 1978 - 1980
Harvard Medical SchoolPhD, 1974 - 1978
Harvard Medical SchoolClass of 1978
Certifications & Licensure
CA State Medical License 1979 - Present
NY State Medical License 1987 - 2027
OH State Medical License 1982 - 1988
American Board of Pediatrics Pediatrics
Awards, Honors, & Recognition
- The Society of Memorial Sloan Kettering (MSK) Prize Society of Memorial Sloan Kettering, 2026
- Lifetime Achievement Award Advances in Neuroblastoma Research Association, 2025
- America's Top Doctors Castle Connolly, 2012-2017
Clinical Trials
- Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma in Second Remission
- Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma
- Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma
Publications & Presentations
PubMed
- A phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in second or later complete remission.Brian H Kushner, Shakeel Modak, Charlie White, Ellen M Basu, Stephen S Roberts
International Journal of Cancer. 2026-06-15 - Establishment ofGa-DOTA-Based Pretargeted Radioimmunodiagnosis.Darren R Veach, Daniela Burnes Vargas, Baharul Islam, Sang Gyu Lee, Leah Gajecki
Molecular Pharmaceutics. 2026-06-01 - T cell-engaging bispecific antibodies for myeloid malignancies: Targets, formats, and clinical challenges.Sophie Paczesny, Sonali P Barwe, Anilkumar Gopalakrishnapillai, Nai-Kong V Cheung
Cell Reports. Medicine. 2026-05-19
Grant Support
- Phase I Study Of Humanized 3F8 Monoclonal Antibody (HU3F8) In Patients With High-National Cancer Institute2011
- Modulation By Botanicals Of Antibody Based Cancer ImmunotherapyNational Center For Complementary &Alternative Medicine2007–2009
- Project 4National Cancer Institute2005–2009
- A Novel SET Of Molecular Markers To Measure Metastatic NeuroblastomaNational Cancer Institute2006–2007
- Modulation By Botanicals Of Antibody Based Cancer ImmunoNational Center For Complementary &Alternative Medicine2005–2006
Other Languages
- Chinese (Cantonese)
External Links
- Physician Biographyhttp://www.mskcc.org/prg/prg/bios/203.cfm
- Laboratory Researchhttp://www.mskcc.org/mskcc/html/55349.cfm
- MSKCC neuroblastoma websitehttp://www.mskcc.org/mskcc/html/2868.cfm
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
